Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Q32 Bio's Bempikibart?
Bempikibart is a monoclonal antibody commercialized by Q32 Bio, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema)....
Data Insights
Bempikibart by Q32 Bio Operations for Alopecia Areata: Likelihood of Approval
Bempikibart is under clinical development by Q32 Bio Operations and currently in Phase II for Alopecia Areata. According to GlobalData,...